Neos Therapeutics, Inc. (NEOS) financial statements (2021 and earlier)

Company profile

Business Address 2940 N. HIGHWAY 360
GRAND PRAIRIE, TX 75050
State of Incorp. DE
Fiscal Year End December 31
SIC 2834 - Pharmaceutical Preparations (benchmarking)
More info Complete financial analysis Financial benchmarking

Balance sheet (Statement of financial position) ($ in millions)

12/31/2019
Q4
9/30/2019
Q3
6/30/2019
Q2
3/31/2019
Q1
12/31/2018
Q4
9/30/2018
Q3
6/30/2018
Q2
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments25253040461728
Cash and cash equivalents17232633461718
Short-term investments8247  10
Receivables27292023282018
Inventory, net of allowances, customer advances and progress billings11121211101213
Inventory11121211101213
Other current assets 223411
Other undisclosed current assets4      
Total current assets:67686577895060
Noncurrent Assets
Operating lease, right-of-use asset33  
Property, plant and equipment7888888
Intangible assets, net (including goodwill)13131414151516
Intangible assets, net (excluding goodwill)13131414151516
Other noncurrent assets1000000
Other undisclosed noncurrent assets  33   
Total noncurrent assets:24242525232324
TOTAL ASSETS:9192891021117384
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities47444043493740
Accounts payable77791386
Accrued liabilities40383434363034
Debt22 991616
Other undisclosed current liabilities1515171   
Total current liabilities:63615752575356
Noncurrent Liabilities
Long-term debt and lease obligation, including:44 43434444
Finance lease, liability00  
Operating lease, liability33  
Other undisclosed long-term debt and lease obligation   43434444
Liabilities, other than long-term debt1122333
Deferred revenue and credits1
Deferred rent credit    11 
Other liabilities0000000
Derivative instruments and hedges, liabilities1112211
Other undisclosed noncurrent liabilities2928324   
Total noncurrent liabilities:34343449464646
Total liabilities:979591101104100103
Stockholders' equity
Stockholders' equity attributable to parent(6)(3)(2)18(27)(19)
Common stock0000000
Treasury stock, value(0)(0)(0)(0)(0)(0)(0)
Additional paid in capital328328327326325281277
Accumulated other comprehensive income (loss)0 0(0)  0
Accumulated deficit(334)(330)(328)(325)(317)(308)(295)
Total stockholders' equity:(6)(3)(2)18(27)(19)
TOTAL LIABILITIES AND EQUITY:9192891021117384

Income statement (P&L) ($ in millions)

12/31/2019
Q4
9/30/2019
Q3
6/30/2019
Q2
3/31/2019
Q1
12/31/2018
Q4
9/30/2018
Q3
6/30/2018
Q2
Revenues17181615151311
Cost of revenue
(Cost of Goods and Services Sold)
(7)(6)(5)(6)(8)(7)(7)
Gross profit:1011118864
Operating expenses(11)(12)(13)(14)(15)(16)(18)
Operating loss:(2)(0)(2)(6)(7)(10)(13)
Nonoperating income
(Other Nonoperating income)
0010000
Interest and debt expense(2)(2)(2)(2)(2)(2)(2)
Loss from continuing operations before income taxes:(3)(2)(4)(8)(9)(13)(15)
Other undisclosed loss from continuing operations(0)      
Net loss available to common stockholders, diluted:(3)(2)(4)(8)(9)(13)(15)

Comprehensive Income ($ in millions)

12/31/2019
Q4
9/30/2019
Q3
6/30/2019
Q2
3/31/2019
Q1
12/31/2018
Q4
9/30/2018
Q3
6/30/2018
Q2
Net loss:(3)(2)(4)(8)(9)(13)(15)
Comprehensive loss:(3)(2)(4)(8)(9)(13)(15)
Other undisclosed comprehensive income (loss), net of tax, attributable to parent0(0)0(0) (0)0
Comprehensive loss, net of tax, attributable to parent:(3)(2)(4)(8)(9)(13)(15)

Statements sources

The financial statements are based on the company's filings with the The U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: